Schizophrenia and autism represent neurodevelopmental disorders that are highly genetic, with monozygotic concordance rates of approximately 45% and 91% respectively (Sullivan et al., 2003; Bailey et al., 1995) . Clearly, however, environmental factors which contribute to the genesis of both disorders play major roles in their etiopathologies (Fatemi 2008; Realmuto and Azeem, 2008) . By far the most important environmental risks for both diseases consist of intrauterine infections (Brown, 2006; Patterson, 2007) . Indeed, based on some reports, up to 21% of schizophrenia cases may be due to maternal infection (Penner and Brown, 2007) .
Autism is characterized by the presence of social and language deficits, and repetitive behavior (APA, 1994) . Pathologic findings of the brain show abnormalities including macrocephaly (Courchesne et al., 2003) and minicolumnar pathology (Casanova et al., 2002) , which point to a neurodevelopmental origin. Molecular and neuropathologic abnormalities in autism (Palmen et al., 2004) include decreased levels of Reelin and Bcl-2 and increased levels of P53, causing cortical dysgenesis (Fatemi et al., 2005b; Fatemi and Halt, 2001) ; GABAergic derangements such as decreased glutamic acid decarboxylase 65/67 levels (Fatemi et al., 2002; Blatt, 2005) and GABA A and B receptor abnormalities (Fatemi et al., 2009a,b; Oblak et al., 2009) , and cholinergic alterations (Perry et al., 2001) . Several of these abnormalities have also been associated with virally mediated animal models for autism (Meyer et al., 2009 ) and immune activation (Laurence and Fatemi, 2005; Vargas et al., 2005) .
In a series of studies spanning over a decade, Fatemi et al. showed that maternal infection of mice with an H1N1 strain of human influenza virus at various gestational periods resulted in the development of brain structural (Fatemi et al., 1999 (Fatemi et al., , 2008 , genetic (Fatemi et al., 2005a ,b, 2008 ), behavioral (Shi et al., 2003 , and neurochemical (Fatemi et al., 2008) abnormalities in the offspring which resemble several anomalies observed in cases of autism and schizophrenia. Similar experiments using poly I:C have replicated the validity of above experiments and extended the tenet that maternal immune activation can also lead to brain structural and behavioral abnormalities in offspring of exposed rodents (Meyer et al., 2009 ). Indeed, other animal models of immune activation using bacterial lipopolysaccharide (LPS) and periodontal bacteria have pointed to major roles of proinflammatory cytokines such as interleukin 6 (IL-6) in causation of most pathologies in fetal brain (Patterson, 2009) .
The question then arises that if proinflammatory cytokines, either directly or indirectly, lead to such havoc in pregnancies, can we take steps to prevent or diminish the deleterious effects on developing brains in fetuses? As discussed later in this issue, these authors (Parker-Athill et al., 2009 ) elegantly show how the use of flavonoids can act as prophylaxis to prevent IL-6-induced behavioral deficits in offspring of C57BL/6 mice exposed to IL-6 at embryonic date 12.5 (E12.5). The investigators show that luteolin, a citrus derived flavonoid, and its analogue diosmin, inhibit neuronal Janus kinase 2/signal transducer and activator or transcription 3 (JAK2/STAT3) phosphorylation both in vivo and in vitro following IL-6 challenge and significantly diminish behavioral deficits in social interaction in this rodent model of maternal immune activation (MIA). Members of the JAK-STAT family of signaling pathway molecules (Cattaneo et al., 1999; Schindler et al., 2007) are cytoplasmic proteins which upon activation by cytokines mediate a number of cellular processes including cell death, cell proliferation, and cell differentiation (Stephanou and Latchman, 2005) . JAK2 receptors are stimulated by IL-3 and IFN-γ cytokines. STAT3 activity, in turn, is regulated by tyrosine kinase JAK2 (Saltzman et al., 1998) . However, STAT3 is known to transduce IL-6, IL-10, GCSF, leptin, IL-21, and IL-27 signals. Additionally, STAT3 is involved in anti-apoptotic gene actions (Schindler et al., 2007) . Recent evidence has suggested that disruption of the JAK2/STAT3 pathway by amyloid-β may lead to memory impairment in subjects with Alzheimer's disease (Chiba et al., 2009 ). Additionally, several reports implicate involvement of JAK-STAT signaling in actions of LPS and influenza-mediated immune activation (Zhang et al., 2006; Sriram et al., 2004) .
The current study (Parker-Athill et al., 2009) , replicates the use of anti IL-6 antibody which also blocked the effects of MIA on the behavior of the offspring as recently shown by Patterson et al. (Smith et al., 2007) . Importantly, Parker-Athill et al. in this issue, identify a potential treatment to counteract the negative effects of influenza infection on the fetus, possibly preventing the development of neurodevelopmental disorders, including autism. Interestingly, Pang et al. (2006) showed that anti IL-6 antibody can also diminish LPS-induced ventricular dilatation, astrocytic activation, and reduce behavioral abnormality. Clearly, more mechanistic studies are needed to explain the role of numerous brain genes which become activated during viral infection of the fetal brain (Fatemi et al., 2008) . Recent unpublished preliminary experiments performed in the author's laboratory have shown the protective effects of oseltamivir in reducing the effects of viral infection in C57BL/6 E16 mice, whereby induction of virally-induced hippocampal gene transcription was reduced significantly at birth (Fatemi et al., unpublished observations) . This effect was clearly due to the neurominidase inhibitory effect of oseltamivir on maternal immune system benefiting the fetal brain from direct viral effects.
Studies such as those performed by Parker-Athill et al. are needed to identify additional pathways for intervention in prevention of immune-mediated brain disorders like schizophrenia and autism. Indeed, the available literature points to the usefulness of agents such as flavonoids (Nagai et al., 1995; Wang et al., 2006; Liu et al., 2008) , macrolides (Kido et al, 2007; Miyamoto et al., 2008) , pentoxifylline
